Next Article in Journal
Patterns of Antibiotic Prescription in Endodontic Therapy in the Republic of Croatia
Next Article in Special Issue
Local Antimicrobial Therapy with Combined Aminoglycoside and Vancomycin Compared to Aminoglycoside Monotherapy in the Surgical Management of Osteomyelitis and Fracture-Related Infection
Previous Article in Journal
Point Mutations in Furazolidone and Rifampicin Resistance Genes in Helicobacter pylori Strains from Colombia
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study

1
Service des Maladies Infectieuses et Tropicales, Hôpital Raymond-Poincaré, 92380 Garches, France
2
Service de Maladies Infectieuses, CHU d’Orléans, 45100 Orléans la Source, France
3
Service des Maladies Infectieuses et Tropicales, Université Côte d’Azur, CHU Nice, 06200 Nice, France
4
Public Health Expertise, 75004 Paris, France
5
Unité de Maladies Infectieuses et Tropicales, CH de Valenciennes, 59300 Valenciennes, France
6
Cibles et Médicaments des Infections et de L’immunité, CHU Nantes, Nantes Université, 44000 Nantes, France
7
Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier Tourcoing, 59208 Tourcoing, France
*
Author to whom correspondence should be addressed.
Antibiotics 2024, 13(7), 644; https://doi.org/10.3390/antibiotics13070644
Submission received: 20 May 2024 / Revised: 6 July 2024 / Accepted: 10 July 2024 / Published: 12 July 2024
(This article belongs to the Special Issue Orthopedic Infections: Epidemiology and Antimicrobial Treatment)

Abstract

Objectives. To identify the current practices with long half-life lipoglycopeptides (LGPs) and potential use/position of oritavancin. Results. Despite their indication being limited to skin and soft tissue infections (SSTIs), long half-life lipoglycopeptides are mainly used off-label to treat bone and joint infections (BJIs) and infective endocarditis. Oritavancin and dalbavancin are both semisynthetic lipoglycopeptide antibiotics with activity against Gram-positive organisms. The game-changing property of these two antibiotics is their one-time dosing. Due to its shorter half-life, oritavancin might have an advantage over dalbavancin for a treatment duration of less than 2 weeks, as it could be used both in prolonged treatments of complicated patients in BJIs or administered as a single-dose treatment for Gram-positive cocci infections usually treated by a 5- to 10-day antibiotic course. These infections include urinary tract infections, bacteremias, catheter-related infections, etc. In addition to the possibility of being used as an end-of-treatment injection, oritavancin could be used as an empiric therapy treatment in the postoperative period in the context of device-associated especially prosthetic joint infections to allow for the early discharge of the patient. Methods. A qualitative survey was conducted in March 2022 including sixteen infectiologists, one internist, five hospital pharmacists, and one pharmacologist. Conclusion. Long half-life lipoglycopeptides contribute to changing the paradigm in the management of acute bacterial infections, as infectiologists now consider a range of indications and patient profiles for one single drug. Oritavancin strengthens the therapeutic arsenal in numerous infections from BJIs to urinary tract infections and could help to manage specific clinical situations, on top of providing potential benefits for the hospital’s budget.
Keywords: oritavancin; long half-life lipoglycopeptides; long-acting antibiotics; acute bacterial infections; Gram-positive; hospital discharge oritavancin; long half-life lipoglycopeptides; long-acting antibiotics; acute bacterial infections; Gram-positive; hospital discharge

Share and Cite

MDPI and ACS Style

Dinh, A.; Béraud, G.; Courjon, J.; Le Goff, Y.; Ettahar, N.K.; Grégoire, M.; Senneville, E. What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study. Antibiotics 2024, 13, 644. https://doi.org/10.3390/antibiotics13070644

AMA Style

Dinh A, Béraud G, Courjon J, Le Goff Y, Ettahar NK, Grégoire M, Senneville E. What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study. Antibiotics. 2024; 13(7):644. https://doi.org/10.3390/antibiotics13070644

Chicago/Turabian Style

Dinh, Aurélien, Guillaume Béraud, Johan Courjon, Yann Le Goff, Nicolas Kader Ettahar, Matthieu Grégoire, and Eric Senneville. 2024. "What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study" Antibiotics 13, no. 7: 644. https://doi.org/10.3390/antibiotics13070644

APA Style

Dinh, A., Béraud, G., Courjon, J., Le Goff, Y., Ettahar, N. K., Grégoire, M., & Senneville, E. (2024). What Place Is There for Long-Acting Antibiotics in the Management of Gram-Positive Infections? A Qualitative Cross-Sectional Study. Antibiotics, 13(7), 644. https://doi.org/10.3390/antibiotics13070644

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop